MedTrace Logo

First in Human of Single and Multiple Doses of MOR106

NCT02739009 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 81

Last updated 2017-10-05

No results posted yet for this study

Summary

This is a randomized, double-blind, placebo-controlled, dose-escalation, phase I study for the assessment of safety, tolerability and pharmacokinetics of single ascending doses of MOR106 in healthy male subjects and multiple ascending doses in subjects with moderate to severe atopic dermatitis.

Conditions

  • Healthy
  • Dermatitis, Atopic

Interventions

DRUG

MOR106 single ascending doses, intravenous

DRUG

Placebo single ascending doses, intravenous

DRUG

MOR106 multiple ascending doses, intravenous

DRUG

Placebo multiple intravenous administrations

Sponsors & Collaborators

  • MorphoSys AG

    collaborator INDUSTRY

  • Galapagos NV

    lead INDUSTRY

Principal Investigators

  • Helen Timmis, MBChB · Galapagos NV

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-04-30
Primary Completion
2017-08-01
Completion
2017-08-01

Countries

  • Belgium
  • Hungary
  • Moldova
  • Romania

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02739009 on ClinicalTrials.gov